Post · bonfire.cafe

@hildabast@mastodon.online · 2 weeks ago

More progress internationally on next generation Covid vaccines – with a setback in the US:

- More good news on the vaccine for people with immunosuppression

- Progress in intranasal vaccine trials in France & the US

- Approval application for first nextgen vaccine in the US shelved because of new regulations

Plus clinical & preclinical results in my update this month @PLOS now online https://absolutelymaybe.plos.org/2025/11/30/more-progress-on-next-generation-covid-vaccines-and-a-setback-in-the-us-update-no-35/
#Vaccines #Covid #Covid19

Ducky 🇨🇦

@ducky@mstdn.ca replied · 2 weeks ago

@hildabast Psst! I see some empty bullet points on Firefox.

This image shows two of the empty bullet points, but I counted five in total in your post.

Some text with four bullet points, the middle two of which have no text next to them.

Regezi

@Regez@troet.cafe replied · 2 weeks ago

@hildabast
To this day, I still don't understand why the nasal vaccine against influenza has only been approved for children up to the age of 18 here in Europe—the additional benefit of mucosal activation would also be interesting for adults and would be helpful for an overall assessment of experience with this form of vaccination...

@PLOS

soaproot

@soaproot@sfba.social replied · 2 weeks ago

@Regez Don't know about European approvals in particular, but my impression is that the results of the nasal influenza vaccine haven't been as impressive as people had been hoping for. @hildabast @PLOS

bonfire.cafe

A space for Bonfire maintainers and contributors to communicate

bonfire.cafe: About · Code of conduct · Privacy · Users · Instances

Bonfire social · 1.0.1-alpha.8 no JS en

Automatic federation enabled